Health Care & Life Sciences » Biotechnology | ReNeuron Group PLC

ReNeuron Group PLC | Cash Flow

Fiscal year is April-March. All values GBP Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,820.00
10,303.00
12,846.00
18,165.00
20,967.00
Depreciation, Depletion & Amortization
112.00
125.00
92.00
169.00
232.00
Other Funds
6,000.00
6,000.00
48,283.00
23,347.00
14,525.00
Funds from Operations
6,428.00
8,733.00
12,180.00
14,491.00
14,277.00
Changes in Working Capital
485.00
579.00
605.00
2,375.00
227.00
Net Operating Cash Flow
5,943.00
8,154.00
11,575.00
12,116.00
14,504.00
Capital Expenditures
121.00
380.00
293.00
532.00
235.00
Net Investing Cash Flow
121.00
380.00
293.00
532.00
235.00
Issuance/Reduction of Debt, Net
1.00
1.00
-
-
-
Net Financing Cash Flow
17,434.00
5,999.00
16,912.00
23,347.00
14,525.00
Net Change in Cash
11,370.00
2,535.00
5,044.00
10,699.00
214.00
Free Cash Flow
6,064.00
8,215.00
11,868.00
12,648.00
14,739.00
Change in Capital Stock
23,435.00
-
65,195.00
-
-

About ReNeuron Group

View Profile
Address
Pencoed Business Park
Pencoed BJ CF35 5HY
United Kingdom
Employees -
Website http://reneuron.com
Updated 07/08/2019
ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. It develops its core stem cell assets such as CTX neural cell line and human retinal progenitor cells. The company was founded by John David Sinden in 1997 and is headquartered in Pencoed, the United Kingdom.